Journal
LUNG CANCER
Volume 109, Issue -, Pages 145-146Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2017.03.005
Keywords
Malignant mesothelioma; BAP1; Mutation; Loss; Targeting; Inhibitor
Categories
Ask authors/readers for more resources
New treatment strategies for malignant pleural mesothelioma (MPM) are important. BAP1 mutations are present in 47-67% of the MPM tumors, making this a good target for treatment. Multiple functions of BAP1 are investigated in the preclinical situation. Due to many functions of BAP1, the phenotypic effect of BAP1 is diverse. Preclinical data on inhibitors reversing these phenotypic effects are promising. However, the mechanism of BAP1 is not fully elucidated yet and further research about the mechanism and possible inhibitors is necessary. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
